Epidemiology and analysis of invasive fungal infections in patients with hematological malignancies: a single-center real-life experience

Basit Öğe Kaydı
dc.contributor.authorSoyer, Nur
dc.contributor.authorUnal, Hatice Demet Kiper
dc.contributor.authorVural, Filiz
dc.contributor.authorSahin, Fahri
dc.contributor.authorTobu, Mahmut
dc.contributor.authorDonmez, Ayhan
dc.contributor.authorTombuloglu, Murat
dc.contributor.authorArda, Bilgin
dc.contributor.authorSaydam, Güray
dc.date.accessioned2019-10-27T11:19:40Z
dc.date.available2019-10-27T11:19:40Z
dc.date.issued2017
dc.departmentEge Üniversitesien_US
dc.description.abstractBackground/aim: Invasive fungal infection (IFI) causes morbidity and mortality among patients with hematological malignancies. We evaluated the incidence and treatment characteristics of IFIs between October 2012 and December 2013. Materials and methods: Patients who received chemotherapy or stem cell transplantation were retrospectively evaluated. Fungal infections were classified according to EORTC criteria. Results: Prophylaxis and antifungal therapy were given in 30.5% and 23.6% of 522 chemotherapy courses, respectively. The incidence of proven/probable IFI was 6.7%. The incidence of IFI among patients who received prophylaxis was significantly higher than among those who did not receive it (11.3% vs. 4.6%, P = 0.005). There was no significant difference between patients who received mold-active and no mold-active prophylaxis (P = 0.098). The most common single agent therapy and causative pathogen was liposomal amphotericin B (57.1%) and Aspergillus (n = 5), respectively. IFI-attributable mortality rate was 14.2% in 6 weeks. Conclusion: The IFI incidence and mortality rate were similar to that reported in the literature. The IFI rate was higher in the group using prophylaxis, as this is a high-risk group. Although the IFI rate was not significantly different between groups using prophylaxis, patients should be followed closely for the effective use of posaconazole prophylaxis.en_US
dc.identifier.doi10.3906/sag-1611-90en_US
dc.identifier.endpage1542en_US
dc.identifier.issn1300-0144
dc.identifier.issn1303-6165
dc.identifier.issue5en_US
dc.identifier.pmid29151329en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage1535en_US
dc.identifier.urihttps://doi.org/10.3906/sag-1611-90
dc.identifier.urihttps://hdl.handle.net/11454/32812
dc.identifier.volume47en_US
dc.identifier.wosWOS:000414976900031en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTubitak Scientific & Technical Research Council Turkeyen_US
dc.relation.ispartofTurkish Journal of Medical Sciencesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectInvasive fungal infectionen_US
dc.subjecttreatmenten_US
dc.subjectprophylaxisen_US
dc.subjecthematological malignanciesen_US
dc.subjectepidemiologyen_US
dc.titleEpidemiology and analysis of invasive fungal infections in patients with hematological malignancies: a single-center real-life experienceen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu